UI 064
Alternative Names: UI-064Latest Information Update: 17 Mar 2024
At a glance
- Originator Korea United Pharm Inc
- Class Antiallergics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Allergic rhinitis
Most Recent Events
- 04 Mar 2024 UI 064 is available for licensing as of 04 Mar 2024. https://www.kup.co.kr/main.do
- 04 Mar 2024 Phase-III clinical trials in Allergic rhinitis in South Korea (PO) before March 2024 (Korea United Pharm pipeline, March 2024)
- 04 Mar 2024 Korea United Pharm Inc plans to launch UI 064 for Allergic rhinitis (PO, Tablet) in 2026 (Korea United Pharm Inc pipeline, March 2024)